156 related articles for article (PubMed ID: 35616231)
1. Pricing of HPV tests in Italian tender-based settings.
Inturrisi F; Berkhof J
J Med Econ; 2022; 25(1):762-768. PubMed ID: 35616231
[TBL] [Abstract][Full Text] [Related]
2. Pricing of HPV vaccines in European tender-based settings.
Qendri V; Bogaards JA; Berkhof J
Eur J Health Econ; 2019 Mar; 20(2):271-280. PubMed ID: 30051152
[TBL] [Abstract][Full Text] [Related]
3. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
4. Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China.
Li Z; Liu C; Zuo K; Liu J; Tang Y
Front Pharmacol; 2021; 12():741671. PubMed ID: 34721029
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and cost of cervical cancer care and prevention in Apulia (Italy), 2007/2016.
Bianchi FP; Gallone MS; Fortunato F; Boccalini S; Martinelli D; Prato R; Tafuri S
Ann Ig; 2018; 30(6):490-501. PubMed ID: 30614498
[TBL] [Abstract][Full Text] [Related]
7. [Implementation of DNA-HPV primary screening in Italian cervical cancer screening programmes. Results of the MIDDIR Project].
Di Stefano F; Giorgi Rossi P; Carozzi F; Ronco G; Cacciani L; Vecchi S; Naldoni C; Segnan N;
Epidemiol Prev; 2017; 41(2):116-124. PubMed ID: 28627153
[TBL] [Abstract][Full Text] [Related]
8. Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea.
Nguyen DTN; Simms KT; Keane A; Mola G; Bolnga JW; Kuk J; Toliman PJ; Badman SG; Saville M; Kaldor J; Vallely A; Canfell K
BMJ Glob Health; 2022 Mar; 7(3):. PubMed ID: 35241461
[TBL] [Abstract][Full Text] [Related]
9. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.
Maver PJ; Poljak M
Clin Microbiol Infect; 2020 May; 26(5):579-583. PubMed ID: 31539637
[TBL] [Abstract][Full Text] [Related]
10. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
[TBL] [Abstract][Full Text] [Related]
11. Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening.
Poljak M; Cuschieri K; Waheed DE; Baay M; Vorsters A
Acta Dermatovenerol Alp Pannonica Adriat; 2021 Mar; 30(1):21-26. PubMed ID: 33765753
[TBL] [Abstract][Full Text] [Related]
12. Does managed competition constrain hospitals' contract prices? Evidence from the Netherlands.
Douven R; Burger M; Schut F
Health Econ Policy Law; 2020 Jul; 15(3):341-354. PubMed ID: 30973119
[TBL] [Abstract][Full Text] [Related]
13. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
14. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
Campos NG; Castle PE; Wright TC; Kim JJ
Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
[TBL] [Abstract][Full Text] [Related]
16. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
[TBL] [Abstract][Full Text] [Related]
17. The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian's structure-process-outcome framework.
Wang Q; Liu S; Nie Z; Zhu Z; Fu Y; Zhang J; Wei X; Yang L; Wei X
J Glob Health; 2023 Nov; 13():04137. PubMed ID: 37947028
[TBL] [Abstract][Full Text] [Related]
18. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.
Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K
Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759
[TBL] [Abstract][Full Text] [Related]
19. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]